Roche CEO drags Arcus, iTeos lower after comments on cancer trial

Feb. 02, 2023 9:29 AM ETiTeos Therapeutics, Inc. (ITOS), RCUSRHHBY, CGEN, RHHBF, BGNEBy: Dulan Lokuwithana, SA News Editor

Roche company office building

Robert Way

iTeos Therapeutics (NASDAQ:ITOS) and Arcus Biosciences (NYSE:RCUS) were among notable decliners in pre-market trading Thursday after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) CEO commented on its SKYSCRAPER-01 trial, which evaluated the anti-TIGIT immunotherapy tiragolumab in lung cancer.

Biotechs iTeos (

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.